SutroVax picks up $85 million in Series C round for pneumococcal vaccine
SutroVax, spun off from Sutro Biopharma, also announced a contract manufacturing deal with Swiss vendor Lonza.
SutroVax, spun off from Sutro Biopharma, also announced a contract manufacturing deal with Swiss vendor Lonza.
Bay Area startup SutroVax just raised $22 million for work in developing conjugate vaccines - and likely improving upon existing inoculations for pneumococcal conditions.
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.